After 50 Years, a New Lupus Drug Finally Emerges – If Approved, How Will Benlysta Impact the Market?

— A Pharmacor Analyst Call from Decision Resources

Based on our 2009 Pharmacor Systemic Lupus Erythematosus report, Decision Resources is offering an exclusive analyst call entitled After 50 Years, a New Lupus Drug Finally Emerges – If Approved, How Will Benlysta Impact the Market? Because this analyst call will feature report findings, it is ONLY available to purchasers of this report.

Please contact us to learn how you can purchase this report and attend the analyst call.

During the recent Scientific Meeting of the American College of Rheumatology and in company-reported results, GlaxoSmithKline and Human Genome Sciences announced promising clinical trial data regarding Benlysta (belimumab) for the treatment of systemic lupus erythematosus (SLE). In the trial, Benlysta was shown to reduce the symptoms of SLE and, as a result of its efficacy, GlaxoSmithKline and Human Genome Sciences announced that they will file for regulatory approval of the drug in both the United States and Europe in 2010. If approved, Benlysta could become the first new drug approved for systemic lupus erythematosus in 50 years.

Following the conference, Decision Resources Analyst Dancella Fernandes, Ph.D., surveyed 30 U.S. rheumatologists to determine their reaction to the news that emerged from the event. Additionally, as a result of the pending submission for regulatory approval of Benlysta, Decision Resources will update its Systemic Lupus Erythematosus report.

In this 15-minute analyst call, Dr. Fernandes will answer the following questions:

• What impact will Benlysta have on the SLE market if the agent receives regulatory approval? If approved, how do surveyed rheumatologists expect to use Benlysta and for which patient segments do they expect to prescribe it?
• How will the scope of Benlysta’s likely label indication shape its use in the SLE market? What will be the most significant drivers of Benlysta’s use and what do surveyed experts think could be potential barriers to its uptake?
• What are Decision Resources’ expectations for Benlysta’s commercial success?

Dr. Fernandes will conduct a live Q & A session after the presentation.

Registration

After 50 Years, a New Lupus Drug Finally Emerges – If Approved, How Will Benlysta Impact the Market?

November 20, 2009 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To learn how you can purchase this Pharmacor report and attend the analyst call, please contact us using the information below.

Contact Us

In North America — Steve Silvestro at 781-296-2626 or ssilvestro@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2009 Decision Resources, Inc. All rights reserved.